Alimera Sciences Inc., an Atlanta-based ophthalmic pharmaceutical company, has set its IPO terms to six million common shares being offered at between $15 and $17 per share. It would have an initial market cap of approximately $518 million, were it to price at the high end of its range.
The company plans to trade on the Nasdaq under ticker symbol ALIM, with Credit Suisse and Citi serving as co-lead underwriters.
Alimera has raised just over $71 million in VC funding since 2004, from firms like Scale Venture Partners (18.44% pre-IPO stake), Domain Associates (18.44%), Intersouth Partners (18.44%), Polaris Venture Partners (18.44%) and Venrock Associates (14.93%).
It also received a total of $16.7 million from the sale of two OTC allergy products and a lubricating eye from to Bausch & Lomb. www.alimerasciences.com